# Nuclide record vision (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/vision/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "vision", "NCT03511664" ;
  schema:name "VISION"@en ;
  schema:description "VISION was the trial that established radioligand therapy in prostate cancer."@en ;
  schema:url <https://nuclide.cc/trials/vision/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03511664> ;
  nuclide:status "positive" ;
  nuclide:phase "3" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/psma-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:people <https://nuclide.cc/people/oliver-sartor/>, <https://nuclide.cc/people/ken-herrmann/>, <https://nuclide.cc/people/michael-morris/> .